Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Obtained from physician office visit.~* Diagnosis of bacterial conjunctivitis (signs and / or symptoms and / or culture).~* Informed Consent signed and dated (consent of the parents for minor patients).~Exclusion Criteria:~* absence of written informed consent.~* Women of childbearing age, without contraceptive use (oral contraceptive pill, contraceptive intrauterine device, contraceptive implant, patch or condom).~* Pregnant or breastfeeding women.~* Subjects that could not be evaluated partially or totally according to the protocol.~* Subjects with topical, systemic or intravenous medication with any type of antibiotic on the day of the baseline visit.~* Subjects with topical, systemic or intravenous medication with any type of medication that interferes decisively with the results of the study.~* Subjects with a hypersensitivity history to any component or analogues of the formulation product.~* Positive drug addiction (smoking, alcoholism, marijuana).~* Subjects with a history of participation in any clinical study in the last 40 days prior to their evaluation.~* incapacity to give informed consent owing to mental disorder or legal condition.~* Any major anomaly detected during the clinical examination, tests that could interfere with the performance of the study or with the efficacy and safety evaluations.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- PRO-157 BID (2 times per day) (Type: EXPERIMENTAL): 60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~1. instill one drop in each eye of PRO-157 (pazufloxacin), every 12 hours per day (BID), for 7 days~2. instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%)every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)
- PRO-157 TID (3 times per day) (Type: EXPERIMENTAL): 60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~1. instill one drop in each eye of PRO-157 (pazufloxacin), every 8 hours per day (TID), for 7 days~2. 15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)
- PRO-157 QID (4 times per day) (Type: EXPERIMENTAL): 60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~1. instill one drop in each eye of PRO-157 (pazufloxacin), every 6 hours per day (QID), for 7 days~2. 15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)
- Moxifloxacin (Vigamox®) (Type: ACTIVE_COMPARATOR): 60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~1. instill one drop in each eye of Moxifloxacin, every 8 hours per day, for 7 days.~2. 15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days. (Can be applied 15 minutes after moxifloxacin)
- Gatifloxacin (Zymar®) (Type: ACTIVE_COMPARATOR): 60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~1. instill one drop in each eye of Gatifloxacin, every 8 hours per day, for 7 days.~2. 15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days.one drop 4 times a day for 7 days in each eye.(Can be applied 15 minutes after gatifloxacin)

Based on this trial design, predict the completion outcome and termination type (if applicable).